

1. The use of apoptotic bodies and/or apoptotic cells in treatment and/or prophylaxis of a disorder selected from the group consisting of T-cell-mediated and inflammatory disorders in mammalian patients.

10

4. The use of Claim 3 wherein the apoptotic bodies and/or apoptotic cells comprise from 10% to 90% of the cellular portion of the suspension.

15

6. The use of Claim 1 or 2 wherein the apoptotic bodies and/or cells are derived from extracorporeal treatment of blood cells compatible with those of the mammalian patient.

20

8. The use of Claim 6 wherein the blood cells are white blood cells of blood compatible with that of the mammalian patient.

25

10. The use of Claim 9 wherein the blood cells are the patient's own T lymphocytes.

11. The use of Claim 1 or 2 wherein the disorder is selected from the group consisting of psoriasis, rheumatoid arthritis, scleroderma, lupus, diabetes mellitus, organ rejection, miscarriage, multiple sclerosis, inflammatory bowel disease, atherosclerosis, and graft versus host disease.

12. The use of Claim 1 or 2 further comprising administering to the mammalian patient a dosage of apoptotic bodies and/or apoptotic cells comprising from 10,000 to 10,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

13. The use of Claim 12 wherein the dosage comprises from 500,000 to 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

14. The use of Claim 13 wherein the dosage comprises from 1,500,000 to 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

15. A method for treatment of or prophylaxis against T-cell-mediated and inflammatory disorders in a mammalian patient, which comprises administering to the patient an effective amount of apoptotic bodies and/or apoptotic cells.

16. The use of Claim 1 or 2 in preparation of a unit dosage of medicament for administration to a human patient, said dosage containing from 10,000 to 10,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

0586450 053501
105350 0549850

17. The use of Claim 16 wherein the dosage comprises from 500,000 to 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

18. The use of Claim 17 wherein the dosage comprises from 1,500,000 to 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

ADD
B1

05866438-000001
T05250-000001